Saliva and serum lacosamide concentrations in patients with epilepsy

Epilepsia

Volumn 52, Issue 2, 2011, Pages 258-263

  Greenaway, Clare ^a,b   Ratnaraj, Neville ^a,b   Sander, Josemir W ^a,b   Patsalos, Philip N ^a,b  

^a NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

^b Chalfont Centre for Epilepsy   (United Kingdom)

Author keywords

Free concentrations; Lacosamide; New antiepileptic drug; Saliva monitoring; Therapeutic drug monitoring

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; CLOBAZAM; CLONAZEPAM; ETIRACETAM; HARKOSERIDE; LAMOTRIGINE; OXCARBAZEPINE; PHENYTOIN; PREGABALIN; PRIMIDONE; TOPIRAMATE; VALPROIC ACID; ZONISAMIDE;

ADD ON THERAPY; ADJUVANT THERAPY; ADULT; AGED; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG BLOOD LEVEL; DRUG MECHANISM; DRUG MONITORING; DRUG SALIVA LEVEL; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; INTRACTABLE EPILEPSY; LINEAR REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BINDING; SALIVA ANALYSIS;

ACETAMIDES; ADULT; AGED; ANTICONVULSANTS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DOSE-RESPONSE RELATIONSHIP, DRUG; EPILEPSY; FEMALE; HUMANS; LINEAR MODELS; MALE; MIDDLE AGED; SALIVA; YOUNG ADULT;

EID: 79951659549     PISSN: 00139580     EISSN: 15281167     Source Type: Journal    
DOI: 10.1111/j.1528-1167.2010.02751.x     Document Type: Article

References (27)

1. Al Za'abi M, Deleu D, Batchelor C,. (2003) Salivary free concentrations of anti-epileptic drugs: an evaluation in routine clinical practice. Acta Neurol Belg 103: 19-23. (Pubitemid 36411130)
2. Bardy AH, Seppala T, Salokorpi T, Granstrom ML, Santavuori P,. (1991) Monitoring of concentrations of clobazam and norclobazam in serum and saliva of children with epilepsy. Brain Dev 13: 174-177.
3. Ben-Menachem E, Biton V, Jatuzis D, Abou-Khalil B, Doty P, Rudd GD,. (2007) Efficacy and safety of oral lacosamide as adjunctive therapy in adults with partial-onset seizures. Epilepsia 48: 1308-1317. (Pubitemid 47063096)
4. Ben-Menachem E,. (2008) Lacosamide: an investigational drug for adjunctive treatment of partial-onset seizures. Drugs Today 44: 35-40. (Pubitemid 351397411)
5. Beyreuther BK, Freitag J, Heers C, Krebsfanger N, Scharfenecker U, Stohr T,. (2007) Lacosamide: a review of preclinical properties. CNS Drug Rev 13: 21-42. (Pubitemid 46697839)
6. Cardot JM, Degan F, Flesch G, Menge P, Dieterle W,. (1995) Comparison of plasma and saliva concentrations of the active monohydroxy metabolite of oxcarbazepine in patients at steady state. Biopharm Drug Dispos 16: 603-614.
7. Chee KY, Lee D, Byron D, Naidoo D, Bye A,. (1993) A simple collection method for saliva in children: potential for home monitoring of carbamazepine therapy. Br J Clin Pharmacol 35: 311-313. (Pubitemid 23074060)
8. Cross SA, Curran MP,. (2009) Lacosamide: in partial onset seizures. Drugs 69: 449-459.
9. Doty P, Rudd GD, Stoehr T, Thomas D,. (2007) Lacosamide. Neurotherapeutics 4: 145-148. (Pubitemid 46107317)
10. Greenaway C, Ratnaraj N, Sander JW, Patsalos PN,. (2010) A high-performance liquid chromatography assay to monitor the new antiepileptic drug lacosamide in patients with epilepsy. Ther Drug Monit 32: 448-452.
11. Grim SA, Ryan M, Miles MV, Tang PH, Strawburg RH, DeGrauw TJ, Fakhoury TA, Baumann RJ,. (2003) Correlation of levetiracetam concentrations between serum and saliva. Ther Drug Monit 25: 61-66. (Pubitemid 36139827)
12. Halasz P, Kalviainen R, Mazurkiewicz-Beldzinska M, Rosenow F, Doty P, Hebert D, Sullivan T, on behalf of the SP755 Study Group. (2009) Adjunctive lacosamide for partial-onset seizures: efficacy and safety results from a randomized controlled study. Epilepsia 50: 443-453.
13. Johannessen Landmark C, Patsalos PN,. (2010) Drug interactions involving the new second and third generation antiepileptic drugs. Expert Rev Neurother 10: 119-140.
14. Lins RL, Otoul C, De Smedy F, Coupez R, Stockis A,. (2007) Comparison of plasma and saliva concentrations of levetiracetam following administration orally as a tablet and as a solution in healthy adult volunteers. Int J Clin Pharmacol Ther 45: 47-54. (Pubitemid 46343976)
15. Liu H, Delgado MR,. (1999) Therapeutic drug concentration monitoring using saliva samples. Focus on anticonvulsants. Clin Pharmacokinet 36: 453-470. (Pubitemid 29317492)
16. Luszczki JL,. (2009) Third Generation antiepileptic drugs: mechanism of action, pharmacokinetics and interactions. Pharmacol Rep 61: 197-216.
17. Malone SA, Eadie MJ, Addison RS, Wright AW, Dickinson RG,. (2006) Monitoring salivary lamotrigine concentrations. J Clin Neurosci 13: 902-907. (Pubitemid 44666425)
18. Mecarelli O, Li Voti P, Pro S, Romolo FS, Rotolo M, Pulitano P, Accornero N, Vanacore N,. (2007) Saliva and serum levetiracetam concentrations in patients with epilepsy. Ther Drug Monit 29: 313-318. (Pubitemid 47262261)
19. Miles MV, Tennison MB, Greenwood RS,. (1991) Intraindividual variability of carbamazepine, phenobarbital, and phenytoin concentrations in saliva. Ther Drug Monit 13: 166-171.
20. Miles MV, Tang PH, Glauser TA, Ryan MA, Grim SA, Strawburg RH, DeGrauw TJ, Baumann RJ,. (2003) Topiramate concentration in saliva: an alternative to serum monitoring. Pediatr Neurol 29: 143-147. (Pubitemid 37324387)
21. Miles MV, Tang PH, Ryan MA, Grim SA, Fakhoury TA, Strawburg RH, DeGrauw TJ, Baumann RJ,. (2004) Feasibility and limitations of oxcarbazepine monitoring using salivary monohydroxy carbamazepine (MHD). Ther Drug Monit 26: 300-304. (Pubitemid 38703018)
22. Patsalos PN, Berry DJ, Bourgeois BFD, Cloyd JC, Glauser TA, Johannessen SI, Leppik IE, Tomson T, Perucca E,. (2008) Antiepileptic drugs-Best practice guidelines for therapeutic drug monitoring: a position paper by the Subcommission on Therapeutic Drug Monitoring, ILAE Commission on Therapeutic Strategies. Epilepsia 49: 239-1276.
23. Ratnaraj N, Goldberg VD, Hjelm M,. (1990) Temperature effects on the estimation of free levels of phenytoin, carbamazepine and phenobarbitone. Ther Drug Monit 12: 465-472. (Pubitemid 20314040)
24. Rolan P, Sargentini-Maier ML, Pigeolet E, Stockis A,. (2008) The pharmacokinetics, CNS pharmacodynamics and adverse event profile of brivaracetam after multiple increasing oral doses in healthy men. Br J Clin Pharmacol 66: 71-75. (Pubitemid 351822155)
25. Rosenthal E, Hoffer E, Ben-Aryeh H, Badarni S, Benderly A, Hemli Y,. (1995) Use of saliva home monitoring of carbamazepine levels. Epilepsia 36: 72-74.
26. Ryan M, Grim SA, Miles MV, Tang PH, Kakhoury TA, Strawsburg RH, deGrauw TJ, Baumann RJ,. (2003) Correlation of lamotrigine concentrations between serum and saliva. Pharmacotherapy 23: 1550-1557. (Pubitemid 37485307)
27. Tsiropoulos I, Kristensen O, Klitgaard NA,. (2000) Saliva and serum concentration of lamotrigine in patients with epilepsy. Ther Drug Monit 22: 517-521.